Edition:
United Kingdom

People: Novavax Inc (NVAX.OQ)

NVAX.OQ on NASDAQ Stock Exchange Global Select Market

0.52USD
23 Apr 2019
Change (% chg)

$-0.01 (-2.37%)
Prev Close
$0.53
Open
$0.52
Day's High
$0.52
Day's Low
$0.51
Volume
1,170,489
Avg. Vol
2,896,047
52-wk High
$2.58
52-wk Low
$0.49

Young, James 

Dr. James F. Young, Ph.D., is an Independent Chairman of the Board of Novavax, Inc. He is Chairman of the Board and Chief Executive Officer of Targeted Microwave Solutions, Inc. since 2016. Former President, Research and Development, at MedImmune, Inc. Dr. Young has been Chairman of the Board of Novavax, Inc. since April 2011 and a Director since April 2010. Dr. Young held the position of President, Research and Development, at MedImmune, Inc. from 2000 until 2008 and previously served as Executive Vice President, Research and Development from 1999 to 2000, Senior Vice President from 1995 to 1999, and as Senior Vice President, Research and Development from 1989 to 1995. Dr. Young serves as a member of the boards of Targeted Microwave Solutions, Inc. (TGTMF), CannaRoyalty Corp. (CNNRF), and 3-V Biosciences, Inc., a privately-held biopharmaceutical company developing novel antiviral therapeutics. Dr. Young received B.S. degrees in general science and biology from Villanova University, as well as a Ph.D. in microbiology and immunology from Baylor College of Medicine.

Basic Compensation

Total Annual Compensation, USD 92,500
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 441,280
Fiscal Year Total, USD 533,780

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

James Young

533,780

Stanley Erck

2,771,680

John Trizzino

947,747

Gregory Glenn

1,221,250

John Herrmann

913,317

Jody Lichaa

--
As Of  31 Dec 2017